Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. Phase I evaluation found a maximum tolerated rhizoxin dose of 2.6 mg m-2, with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., Heinrich, B., ten Bokkel Huinink, W. W., Wagener, D. J., Aamdal, S., Verweij, J.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 1996
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2074819/
https://ncbi.nlm.nih.gov/pubmed/8980394
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares